Appointment dossier — Ovarian Epithelial Carcinoma

Compounds studied in Ovarian Epithelial Carcinoma

Compounds named in the cited literature for Ovarian Epithelial Carcinoma, labeled by the strongest evidence found:

• Tumor Treating Fields — Phase III trial
• ifosfamide plus etoposide — Phase II trial
• paclitaxel + epirubicin + cisplatin — Phase II trial
• CA125 — Tested in people
• cisplatinum-cyclophosphamide — Tested in people
• melphalan — Tested in people
• paclitaxel plus poldine — Tested in people
• rucaparib — Meta-analysis
• ? — Named in the literature
• 5-fluorouracil — Named in the literature
• abdominopelvic irradiation — Named in the literature
• AdipoR1 — Named in the literature
• adriamycin — Named in the literature
• adriamycin and cis-platinum — Named in the literature
• alpha2beta1-integrin — Named in the literature
• AMHR2-CD — Named in the literature
• anastrozole — Named in the literature
• anlotinib — Named in the literature
• anti-PD-1 — Named in the literature
• aspirin — Named in the literature
• bevacizumab — Named in the literature
• BIBF1120 and SB431542 — Named in the literature
• c-fms ribozyme — Named in the literature
• c-Fos — Named in the literature
• CA 125 — Named in the literature
• carboplatin — Named in the literature
• carboplatin and etoposide — Named in the literature
• carboplatin/paclitaxel — Named in the literature
• CDR3δ-grafted γ9δ2T cells — Named in the literature
• checkpoint inhibitors — Named in the literature
• chemotherapy — Named in the literature
• cisplatin — Named in the literature
• cisplatin, etoposide, bleomycin — Named in the literature
• cisplatinum — Named in the literature
• cisplatinum, cytoxan, adriamycin — Named in the literature
• cyclophosphamide and cisplatin — Named in the literature
• CYH33 — Named in the literature
• dendritic-cell-based immunotherapy — Named in the literature
• docetaxel and carboplatin — Named in the literature
• doxorubicin — Named in the literature

Open recruiting trials (18)

• NCT04657068 · Phase 1 / Phase 2 — A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (United States)
• NCT06730347 · Phase 2 — A Study of Lorigerlimab in Participants With Advanced Solid Tumors (United States)
• NCT06399757 · Phase 1 / Phase 2 — A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors (United States)
• NCT07488676 · Phase 1 / Phase 2 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors (United States)
• NCT05005403 · Phase 1 — Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (United States)
• NCT05799274 · Phase 1 — Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors (United States)
• NCT06508307 · Phase 1 — A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors (China)
• NCT06451497 · Phase 1 — This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors (United States)
• NCT04890613 · Phase 1 — Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation (United States)
• NCT07326111 · Phase 4 — A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese (Germany)
• NCT06412510 · Phase 1 / Phase 2 — Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (United States)
• NCT03983226 · Phase 2 — Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) (China)
• NCT07042802 · Phase 1 / Phase 2 — A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer (China)
• NCT06686030 · Phase 2 — Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer (China)
• NCT06677190 · Phase 2 — Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin (United States)
• NCT07182526 · Phase 2 — Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome (Iraq)
• NCT07030907 · Phase 1 — A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer (United States)
• NCT04811703 · Phase 1 — Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (France)

Most-relevant first: trials that name Ovarian Epithelial Carcinoma, then broader trials you may still qualify for. 622 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Questions to ask your oncologist

1. I've read that Tumor Treating Fields has been studied in people for Ovarian Epithelial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
2. I've read that ifosfamide plus etoposide has been studied in people for Ovarian Epithelial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
3. I've read that paclitaxel + epirubicin + cisplatin has been studied in people for Ovarian Epithelial Carcinoma — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT04657068), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?